Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
February 25, 2020 16:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell...
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting
February 24, 2020 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast...
Allakos Reports Third Quarter 2019 Financial Results
November 12, 2019 16:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast...
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
October 28, 2019 09:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock
August 06, 2019 22:18 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces Proposed Public Offering of Common Stock
August 05, 2019 16:29 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Reports Second Quarter 2019 Financial Results
August 05, 2019 07:15 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)
August 05, 2019 07:00 ET
|
Allakos Inc.
Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001)Treatment response secondary endpoint met with 69% of AK002 treated...
Allakos Reports First Quarter 2019 Financial Results
May 08, 2019 08:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
May 07, 2019 16:01 ET
|
Allakos Inc.
-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference...